C1 esterase inhibitor (recombinant) - Biologic Drug Details

Summary for c1 esterase inhibitor (recombinant)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for c1 esterase inhibitor (recombinant) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for c1 esterase inhibitor (recombinant) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495	12,209,116	2036-11-18	DrugPatentWatch analysis and company disclosures
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495	7,067,713	2021-01-31	DrugPatentWatch analysis and company disclosures
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495	8,071,532	2026-12-19	DrugPatentWatch analysis and company disclosures
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495	RE43691	2024-05-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for c1 esterase inhibitor (recombinant) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495	6,090,777	2016-04-02	Patent claims search
Pharming Americas Bv	RUCONEST	c1 esterase inhibitor (recombinant)	For Injection	125495	9,452,203	2032-12-21	Patent claims search

International Patents for c1 esterase inhibitor (recombinant)

Country	Patent Number	Estimated Expiration
Poland	1965831
World Intellectual Property Organization (WIPO)	2017087882
European Patent Office	1965831
Canada	2632400

C1 esterase inhibitor (recombinant) Market Analysis and Financial Projection

Last updated: February 15, 2026

Market Overview

C1 esterase inhibitor (recombinant) operates within the rare disease space, specifically hereditary angioedema (HAE). The biologic acts by replenishing deficient C1 esterase inhibitor (C1-INH), reducing severity and frequency of HAE attacks. The global HAE market was valued at approximately $1 billion in 2022, projected to reach $2 billion by 2030, with a compound annual growth rate (CAGR) of 8% (source: Grand View Research).

Key Market Drivers

• Increasing diagnosis rate: More awareness and improved diagnostic procedures lead to early detection.
• Limited competition: Only a handful of approved recombinant and plasma-derived treatments for HAE.
• Biologics aging out pipeline: High specificity and safety profile of recombinant C1-INH favor adoption.
• Pricing and reimbursement: Favorable policies for orphan drugs support profitability.

Major Players and Pipeline

Company	Drug Name	Approval Date	Market Position	Pipeline Status
CSL Behring	Haegarda (plasma-derived C1-INH)	2017	Market leader	Developing long-acting formulations, biosimilars
Pharming	Ruconest (recombinant C1-INH)	2008	Second-line	Experimental oral formulations; new subcutaneous delivery methods
Amgen	Amgen C1-INH (investigational)	N/A	Prefile	Pending regulatory submission; phase 3 ongoing

Despite several plasma-derived options, recombinant formulations present advantages, including reduced pathogen transmission risk and improved consistency.

Market Dynamics

Regulatory Landscape

• Approval pathways for biologics, including biosimilar entries, streamline the commercialization process.
• Breakthrough Therapy Designation (FDA) expedites review for promising candidates.
• Regulatory agencies emphasize safety, especially regarding immune responses and pathogen transmission.

Pricing and Reimbursement

• Annual cost per patient ranges from $300,000 to $600,000 (source: IQVIA).
• Reimbursement varies by country; in the U.S., the Centers for Medicare & Medicaid Services (CMS) and private insurers finance approximately 85-90% of treatment costs.

Distribution Channels

• Specialty pharmacies dominate HAE biologics distribution.
• Direct-to-patient delivery methods are expanding with telemedicine growth.

Financial Trajectory

Revenue Projections

• CVS Health predicts that top-selling biologics, including recombinant C1-INH, will maintain or increase market share through 2025.
• The recombinant segment is expected to account for 30-40% of HAE biologic sales in the U.S. by 2025, driven by safety and manufacturing advantages.

Investment vs. Commercialization

• Developments in subcutaneous and oral formulations could reduce administration costs and improve patient compliance.
• The cost of goods for recombinant C1-INH is higher than plasma-derived counterparts, but economies of scale and technological advancements could improve margins.

Cost Factors

• Manufacturing facilities are complex, requiring biofermentation and purification with high standards for sterility.
• R&D investments focus on improving half-life and subcutaneous delivery.
• Patent protection remains critical; however, biosimilar entries could pressure pricing post-expiry.

Risks

• Competition from emerging therapies, including gene editing and small molecules.
• Potential immunogenicity issues with recombinant proteins.
• Pricing pressures in the U.S. market due to policy shifts toward cost containment.

Conclusion

The recombinant C1 esterase inhibitor market is on an upward trajectory, driven by patient needs, technological advancements, and regulatory support. Commercial success hinges on balancing manufacturing costs, patient convenience, and pricing strategies, amid evolving competitive and policy landscapes.

Key Takeaways

• The global HAE biologics market will grow at around 8% CAGR to 2030.
• Recombinant C1-INH features safety and supply chain advantages over plasma-derived products.
• Pricing remains high, but reimbursement policies and biosimilars threaten future margins.
• Development pipelines focus on improving delivery methods and preventing immunogenicity.
• The market is susceptible to regulatory and competitive risks, including emerging gene therapies.

FAQs

Q1: What factors influence the pricing of recombinant C1-INH?
A: Manufacturing complexity, patent status, market exclusivity, and reimbursement policies primarily determine pricing.

Q2: How does biosimilar competition impact this market?
A: Biosimilars could reduce prices and market share for innovator products once patents expire, but current approval pathways delay immediate impacts.

Q3: What are the main safety concerns with recombinant C1-INH?
A: Potential immunogenic reactions, allergic responses, and pathogen transmission risks are monitored during development and post-market.

Q4: How are newer delivery methods expected to influence the market?
A: Subcutaneous and oral formulations may improve patient adherence, reduce healthcare costs, and expand market access.

Q5: What role do regulatory agencies play in shaping market dynamics?
A: Agencies facilitate approval for innovative formulations, expedite reviews for breakthrough therapies, and enforce safety standards, influencing development and commercialization strategies.

References

[1] Grand View Research, "Hereditary Angioedema Treatment Market Size, Share & Trends Analysis Report," 2022.
[2] IQVIA, "Biologic Drug Pricing Trends," 2022.
[3] U.S. FDA, "Biologics License Application (BLA) Approvals."
[4] Pharma Intelligence, "R&D Pipeline for C1-INH in Hereditary Angioedema," 2022.